- In November 2023, the U.S. FDA approved Takeda’s oral targeted therapy, FRUZAQLA (fruquintinib), for adults with metastatic colorectal cancer (mCRC). This chemotherapy-free treatment offers significant survival benefits while minimizing its impact on patients' quality of life. According to Takeda, FRUZAQLA provides an effective option for mCRC patients, offering improved outcomes without the harsh side effects typically associated with traditional treatments
- In August 2023, the U.S. FDA approved LONSURF (trifluridine/tipiracil) from Taiho Pharmaceutical Co., Ltd. and Taiho Oncology, Inc. for the treatment of adult patients with metastatic colorectal cancer (mCRC). This approval allows LONSURF to be used either as a standalone therapy or in combination with bevacizumab. The approval provides a valuable treatment option for mCRC patients, offering flexibility in managing the disease with a combination of therapies
- In June 2023, Enzene Biosciences launched a more affordable version of Bevacizumab for the treatment of metastatic colorectal cancer. This biosimilar drug serves as a cost-effective alternative to the higher-priced Avastin. The launch aims to make treatment more accessible for patients while maintaining the efficacy of the original therapy
